This article announces that Richard Nanula has resigned as the chief financial officer of Amgen Inc.EBSCO_bspWall Street Journal - Eastern Edition
Bradway, chairman and chief executive officer. Key results include: For the first quarter, total revenues increased 22% to $7.4 billion in comparison to the first quarter of 2023. Product sales grew 22%, driven by 25% volume growth. Ten products delivered at least double-digit volume growth...
Kaplan was the Chief Financial Officer of Prevail Therapeutics, which was acquired by Eli Lilly and Company for $940 million. At Evercore Partners, Dr. Kaplan was a Managing Director, Investment Banking advising on strategic and financing transactions. Dr. Kaplan has held other corporate development...
David Meline-- Chief Financial Officer Yeah, so we wanted to communicate the outlook for net price for 2019. And I guess what I would say is that from a macro perspective in the US market, I think we've been quite consistent in expecting that we would see more pressure on ...
Peter Griffith—Executive Vice President and Chief Financial Officer Thank you, Murdo. Consistent with the first half of the year, we executed effectively during the third quarter, delivering 12% revenue and 19% non-GAAP EPS year-over-year growth. As you heard Murdo say, revenue growth was dr...
With us we have both EVP and Chief Financial Officer, David Meline and also Arvind Sood, the VP of Investor Relation here. So again, I just want to thank you both for coming to London, and let me turn the podium to David and then we'll have Q&A later, when Arvind would also join...
More financial data* Estimated data Company Profile Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - ...
and trust of our partners, customers, the public and patients we serve. Robert A. Bradway Chairman and Chief Executive Officer Amgen Amgen reserves the right, in its sole discretion, to modify any aspects of the compliance program, including, without limitation, this book and company policies,...
Lieming Ding, chairman and CEO of Betta Pharma, will serve as chairman of the Amgen-Betta Pharmaceuticals board of directors and James Li, vice president and general manager, Amgen Greater China, will serve as vice-chairman of the board. Yinxiang Wang, president and chief scientific officer of...
M.D., executive vice president, Research and Development, and chief scientific officer at Amgen. "We are grateful for the partnership with patients, clinicians and patient advocacy groups critical to a successful...